Nadine Wong Highlights the Following Stocks: Regeneron, Trimeris, and Aventis.Business Editors CHICAGO--(BUSINESS WIRE)--Sept. 23, 2003 Take advantage of the market's sentiment by bulking up on biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. profits and opportunities. Nadine Wong has a pair of stocks that could prove useful in harnessing the space's momentum. Read about Regeneron (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :REGN), Trimeris (NASDAQ:TRMS TRMS The Rachel Maddow Show (radio program) TRMS Tightrope Media Systems TRMS Tycom Readiness Management System TRMS Training Records Management System TRMS Tuttle Risk Management Services, Inc TRMS Test Resource Management System ), and Aventis (NYSE NYSE See: New York Stock Exchange :AVE). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/ Here are the highlights from the Featured Expert column: Aventis (NYSE:AVE) recently made a deal with Regeneron (NASDAQ:REGN) to develop the biotech company's experimental cancer therapy, VEGF VEGF vascular endothelial growth factor. Trap, and it was a very nice deal for Regeneron. Now all we have to do is wait for the Phase II clinical data. Along with that announcement, the company decided to pursue another Axokine study in obese o·bese adj. Extremely fat; very overweight. obese characterized by obesity. obese adjective Characterized by obesity, see there; excessively fat type 2 diabetic patients, which Nadine Wong believes will decide the true worth of this therapy. She still likes Regeneron, but since its share price has made a nice move with the market, it doesn't hurt to take profits. Meanwhile, Trimeris' (NASDAQ:TRMS) share price is sinking, as Wall Street frets over the sales of the AIDS drug Fuzeon and thinks that the drug isn't going to make the mark. In her September issue, Wong discussed Fuzeon's outlook and stands by her opinion that the drug will prove its worth. However, Wall Street is going to re-adjust its sales projections for Fuzeon. Eventually, Trimeris' share price will bottom out, which will provide a decent entry point for investors. In regards to the overall market, Wong continues to be upbeat. Undoubtedly, September's sentiment will influence investors to take profits. At the same time, she'll take advantage of the conditions, and she'll be adding some new names to her BioPortfolio. Don't stop here! The biotechnology space is always changing and evolving, and Nadine Wong can keep you where the profits are with her in-depth analysis by clicking: http://featuredexpert3bw.zacks.com/ About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail See Internet e-mail service. newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile To translate a program written in a high-level programming language into machine language. See compiler. , analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer (networking) disclaimer - Statement ritually appended to many Usenet postings (sometimes automatically, by the posting software) reiterating the fact (which should be obvious, but is easily forgotten) that the article reflects its author's opinions and not necessarily those of the : Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation solicitation In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual to buy or sell any security. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion